SULFAMYLON CREAM Rx
Generic Name and Formulations:
Mafenide acetate 85mg (base); crm; contains parabens, sodium metabisulfite.
Indications for SULFAMYLON CREAM:
Adjunct in 2nd and 3rd degree burns.
Adults and Children:
Apply 1–2 times daily aseptically with approximately 1/16 inch depth to cleansed and debrided burns. Ensure coverage of burned areas at all times; reapply promptly if removed. May be occluded with a thin layer of dressing, if needed. Continue until wound is healed or site is ready for grafting. Withhold therapy for 24–48 hours if acidosis occurs.
G6PD deficiency. Sulfite sensitivity. Asthma. Acute renal failure. Monitor acid-base balance closely (esp. with extensive 2nd degree or partial thickness burns, pulmonary or renal impairment). Pregnancy (Cat.C); (crm: not recommended for women of childbearing potential; unless burn area >20% of total body surface). Nursing mothers: not recommended.
Application-site pain, burning sensation, allergic manifestations (eg, rash, pruritus, facial edema, swelling, erythema; discontinue if occur), tachypnea, hyperventilation, metabolic acidosis; respiratory alkalosis, fatal hemolytic anemia with disseminated intravascular coagulation, fungal colonization; rare: excoriation of new skin, bleeding of skin.
Crm—2oz, 4oz, 16oz
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Nicotinamide and Cancer
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- Opioid Prescription Protocol Decreases Opioid Use After Gynecologic Surgery
- Everolimus Plus Letrozole May Be Active in Recurrent Endometrial Carcinoma
- Affordable Care Act Increased Percentage of Insured Patients With Gynecologic Cancers
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML